Systems and methods to diagnose sarcoidosis and identify markers of the condition
Systems and methods to diagnose sarcoidosis are described. In addition to diagnosing sarcoidosis, the systems and methods can distinguish sarcoidosis from tuberculosis. Further disclosed is a cDNA library and methods of its use for reliably identifying sarcoidosis markers.
1. A method, comprising
obtaining a sample from a subject; and
assaying the sample for
Ferredoxin (FedA); Transketolase (TKT); and Dihydroxy acid dehydratase (Rv0189C).
2. The method of claim 1 , wherein the sample is a tissue sample, a cell sample, a whole blood sample, a serum sample, a plasma sample, a saliva sample, a sputum sample, or a urine sample; and/or
assaying the sample for one or more markers comprises contacting the sample with a probe comprising a detectable label and that binds the one or more markers; and/or
wherein obtaining a value based on the assay comprises quantitating the amount of the marker in the sample; and/or
the value is a score or a weighted score.
3. The method according to claim 1 , wherein assaying the sample for one or more markers comprises contacting the sample with a probe comprising a detectable label and that binds the one or more markers.
4. The method according to claim 1 , wherein obtaining a value based on the assay comprises quantitating the amount of the marker in the sample.
5. The method according to claim 1 , wherein the value is a score.
6. The method according to claim 5 wherein the score is a weighted score.
7. The method of claim 1 , wherein the sample is further assayed for one or more markers selected from Small inducible cytokine A21 precursor (CCL21); Methionine aminopeptidase 1 (Metap1); Activated RNA polymerase II transcription cofactor variant 4 (PC4); RNA methyltransferase (CLI_3190); Tumor necrosis factor receptor superfamily member 21 precursor (TNFRSF21); Monocyte differentiation antigen CD14 (CD14); DnaJ (Hsp40) homolog subfamily C member 1 precursor (DNAJC1); Amyloid β A4 precursor protein-binding family B member 1-interacting protein (APBB1); Fibroblast growth factor binding protein 2 precursor (FGFBP-2); or SH3 domain-containing YSC84 like protein 1 (SH3YL1).
8. The method of claim 7 , further comprising:
obtaining a value based on the assay;
comparing the value to a reference level;
diagnosing the subject as having tuberculosis based on the upregulation of one or more of FedA, TKT, and/or Rv0189C, as demonstrated by the value and the reference level; and
treating the subject diagnosed as having tuberculosis with a tuberculosis treatment comprising one or more of isoniazid (INH), rifampin (RIF), ethambutol (EMB), or pyrazinamide (PZA).
9. The method of claim 1 , wherein the sample is further assayed for one or markers selected from WDFY3; MFS; LRPPRC; HLA-DR; BfrA; DAB2; or TCEB2.
10. The method of claim 9 , further comprising:
obtaining a value based on the assay;
comparing the value to a reference level;
diagnosing the subject as having tuberculosis based on the upregulation of one or more of FedA, WDFY3, MFS, LRPPRC, HLA-DR, TKT, and/or Rv0189C, or the downregulation of the one or more of BfrA, DAB2, and/or TCEB2, as demonstrated by the value and the reference level; and
treating the subject diagnosed as having tuberculosis with a tuberculosis treatment comprising one or more of isoniazid (INH), rifampin (RIF), ethambutol (EMB), or pyrazinamide (PZA).
11. The method of claim 1 , further comprising:
obtaining a value based on the assay;
comparing the value to a reference level;
diagnosing the subject as having tuberculosis based on the upregulation of one or more of FedA, TKT, and/or Rv0189C, as demonstrated by the value and the reference level; and
treating the subject diagnosed as having tuberculosis with a tuberculosis treatment comprising one or more of isoniazid (INH), rifampin (RIF), ethambutol (EMB), or pyrazinamide (PZA).
12. A method of diagnosing a subject as having sarcoidosis rather than tuberculosis and treating sarcoidosis in the subject, the method comprising:
obtaining a sample derived from the subject;
assaying the sample for Ferredoxin (FedA), Transketolase (TKT), and Dihydroxy acid dehydratase (Rv01890);
obtaining a value based on the assay;
comparing the value to a reference level;
diagnosing the subject as having sarcoidosis rather than tuberculosis based on the up- or down-regulation of the one or more markers as demonstrated by the value and the reference level; and
treating the subject diagnosed as having sarcoidosis with a sarcoidosis treatment comprising one or more of a corticosteroid, methotrexate, azathioprine, hydroxychloroquine, chloroquine, cyclophosphamide, chlorambucil, pentoxifylline and thalidomide, infliximab, adalimumab, colchicine, a nonsteroidal anti-inflammatory drug (NSAID), and/or organ transplantation.
13. The method of claim 12 , comprising further assaying the sample for one or more markers selected from WDFY3 protein (WDFY3); Membrane protein (MFS); Leucine rich PPR-motif containing protein (LRPPRC); HLA-DR alpha (HLA-DR); Chain A Mycobacterium tuberculosis (BfrA); Disabled homolog 2 isoform 2 (DAB2); Transcription elongation factor B polypeptide 2 isoform ( Homo sapiens ) (TCEB2); Small inducible cytokine A21 precursor (CCL21); Methionine aminopeptidase 1 (Metap1); Activated RNA polymerase II transcription cofactor variant 4 (PC4); RNA methyltransferase (CLI_3190); Tumor necrosis factor receptor superfamily member 21 precursor (TNFRSF21); Monocyte differentiation antigen CD14 (CD14); DnaJ (Hsp40) homolog subfamily C member 1 precursor (DNAJC1); Amyloid β A4 precursor protein-binding family B member 1-interacting protein (APBB1); Fibroblast growth factor binding protein 2 precursor (FGFBP-2); or SH3 domain-containing YSC84 like protein 1 (SH3YL1).